Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors
Canine mammary tumor (CMT) is a prevalent and destructive disease often diagnosed at an advanced stage, leading to poor outcomes. Currently, there is a lack of effective biomarkers for early detection and prognostic prediction of CMT. To improve CMT detection, we established a multiplexed immunoassa...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Veterinary Quarterly |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/01652176.2024.2435978 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850174580205813760 |
|---|---|
| author | Chih-Ching Wu Chia-Yu Chang Pei-Yi Chou Xiu-Ya Chan Chun-Chueh Huang Youngsen Yang Hao-Ping Liu |
| author_facet | Chih-Ching Wu Chia-Yu Chang Pei-Yi Chou Xiu-Ya Chan Chun-Chueh Huang Youngsen Yang Hao-Ping Liu |
| author_sort | Chih-Ching Wu |
| collection | DOAJ |
| description | Canine mammary tumor (CMT) is a prevalent and destructive disease often diagnosed at an advanced stage, leading to poor outcomes. Currently, there is a lack of effective biomarkers for early detection and prognostic prediction of CMT. To improve CMT detection, we established a multiplexed immunoassay using a fluorescence bead-based suspension array system to measure serum levels of autoantibodies against four CMT-associated proteins (AGR2, HAPLN1, IGFBP5, and TYMS) in CMT patients. Our data revealed that serum levels of the four autoantibodies (anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS) were significantly elevated in CMT patients (n = 158) compared to healthy individuals (n = 39). Notably, serum levels of anti-AGR2, anti-HAPLN1, and anti-TYMS in the dogs with stage I CMT (n = 56) were higher than those in the healthy group. Using a marker panel consisting of the four autoantibodies for detecting malignant CMT (n = 125) achieved a sensitivity of 50.4% and a specificity of 90%. Furthermore, higher levels of anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS were associated with poorer survival in CMT patients. Collectively, we established a multiplexed immunoassay platform to detect serum autoantibodies and demonstrated that a tailored autoantibody marker panel shows potential clinical applicability for the diagnosis and prognosis of CMT. |
| format | Article |
| id | doaj-art-8f82ae89b3544501b795be5a0dc5261d |
| institution | OA Journals |
| issn | 0165-2176 1875-5941 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Veterinary Quarterly |
| spelling | doaj-art-8f82ae89b3544501b795be5a0dc5261d2025-08-20T02:19:38ZengTaylor & Francis GroupVeterinary Quarterly0165-21761875-59412025-12-0145111210.1080/01652176.2024.2435978Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumorsChih-Ching Wu0Chia-Yu Chang1Pei-Yi Chou2Xiu-Ya Chan3Chun-Chueh Huang4Youngsen Yang5Hao-Ping Liu6Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung, TaiwanDepartment of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung, TaiwanGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Oncology, Taichung Veterans General Hospital, Taichung, TaiwanDepartment of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung, TaiwanCanine mammary tumor (CMT) is a prevalent and destructive disease often diagnosed at an advanced stage, leading to poor outcomes. Currently, there is a lack of effective biomarkers for early detection and prognostic prediction of CMT. To improve CMT detection, we established a multiplexed immunoassay using a fluorescence bead-based suspension array system to measure serum levels of autoantibodies against four CMT-associated proteins (AGR2, HAPLN1, IGFBP5, and TYMS) in CMT patients. Our data revealed that serum levels of the four autoantibodies (anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS) were significantly elevated in CMT patients (n = 158) compared to healthy individuals (n = 39). Notably, serum levels of anti-AGR2, anti-HAPLN1, and anti-TYMS in the dogs with stage I CMT (n = 56) were higher than those in the healthy group. Using a marker panel consisting of the four autoantibodies for detecting malignant CMT (n = 125) achieved a sensitivity of 50.4% and a specificity of 90%. Furthermore, higher levels of anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS were associated with poorer survival in CMT patients. Collectively, we established a multiplexed immunoassay platform to detect serum autoantibodies and demonstrated that a tailored autoantibody marker panel shows potential clinical applicability for the diagnosis and prognosis of CMT.https://www.tandfonline.com/doi/10.1080/01652176.2024.2435978Canine mammary tumorautoantibodybiomarkerserummultiplexed assay |
| spellingShingle | Chih-Ching Wu Chia-Yu Chang Pei-Yi Chou Xiu-Ya Chan Chun-Chueh Huang Youngsen Yang Hao-Ping Liu Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors Veterinary Quarterly Canine mammary tumor autoantibody biomarker serum multiplexed assay |
| title | Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors |
| title_full | Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors |
| title_fullStr | Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors |
| title_full_unstemmed | Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors |
| title_short | Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors |
| title_sort | multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors |
| topic | Canine mammary tumor autoantibody biomarker serum multiplexed assay |
| url | https://www.tandfonline.com/doi/10.1080/01652176.2024.2435978 |
| work_keys_str_mv | AT chihchingwu multiplexedimmunoassayforaserumautoantibodybiomarkerpanelindiagnosticandprognosticpredictionofcaninemammarytumors AT chiayuchang multiplexedimmunoassayforaserumautoantibodybiomarkerpanelindiagnosticandprognosticpredictionofcaninemammarytumors AT peiyichou multiplexedimmunoassayforaserumautoantibodybiomarkerpanelindiagnosticandprognosticpredictionofcaninemammarytumors AT xiuyachan multiplexedimmunoassayforaserumautoantibodybiomarkerpanelindiagnosticandprognosticpredictionofcaninemammarytumors AT chunchuehhuang multiplexedimmunoassayforaserumautoantibodybiomarkerpanelindiagnosticandprognosticpredictionofcaninemammarytumors AT youngsenyang multiplexedimmunoassayforaserumautoantibodybiomarkerpanelindiagnosticandprognosticpredictionofcaninemammarytumors AT haopingliu multiplexedimmunoassayforaserumautoantibodybiomarkerpanelindiagnosticandprognosticpredictionofcaninemammarytumors |